Zacks Investment Research on MSN

VKTX stock jumps on Phase I study initiation for new obesity drug

Shares of Viking Therapeutics VKTX rose about 9% on Wednesday after the company expanded its obesity pipeline by advancing a ...

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today the ...

Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases

In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; ...

Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers

Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment ...
Business Wire

Genethon and Hansa Biopharma Announce Initiation of a Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome

LUND, Sweden & EVRY, France--(BUSINESS WIRE)--Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA) and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, ...
Nasdaq

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

The Phase 1 clinical trial currently recruiting is a pharmacokinetic bridging study in the U.S. designed as a single-dose, single-center, open-label, randomized 2-way crossover study of TH104 and an ...
Yahoo Finance

Actio Biosciences Announces Initiation of KYRON Phase 1b/2 Trial of ABS-1230 for the Treatment of KCNT1-Related Epilepsy and Acceptance into FDA’s Rare Disease Evidence ...

SAN DIEGO, May 08, 2026--(BUSINESS WIRE)--Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel precision medicines, today announced the ...
Nature

Does completion time of the initiation phase of anti-vascular growth factor affect visual and anatomical outcomes?: The MARMASIA study group report No.5

To demonstrate effect of completion time of initiation phase of anti-vascular endothelial growth factor (anti-VEGF) agents on visual and anatomical outcomes in diabetic macular oedema patients. The ...

Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss ...